217 related articles for article (PubMed ID: 27992479)
1. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.
Kirzinger L; Boy S; Marienhagen J; Schuierer G; Neu R; Ried M; Hofmann HS; Wiebe K; Ströbel P; May C; Kleylein-Sohn J; Baierlein C; Bogdahn U; Marx A; Schalke B
PLoS One; 2016; 11(12):e0168215. PubMed ID: 27992479
[TBL] [Abstract][Full Text] [Related]
2. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.
Loehrer PJ; Wang W; Johnson DH; Aisner SC; Ettinger DS;
J Clin Oncol; 2004 Jan; 22(2):293-9. PubMed ID: 14722038
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
Kim ES; Putnam JB; Komaki R; Walsh GL; Ro JY; Shin HJ; Truong M; Moon H; Swisher SG; Fossella FV; Khuri FR; Hong WK; Shin DM
Lung Cancer; 2004 Jun; 44(3):369-79. PubMed ID: 15140551
[TBL] [Abstract][Full Text] [Related]
5. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.
Lucchi M; Ambrogi MC; Duranti L; Basolo F; Fontanini G; Angeletti CA; Mussi A
Ann Thorac Surg; 2005 Jun; 79(6):1840-4. PubMed ID: 15919267
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.
Park S; Ahn MJ; Ahn JS; Sun JM; Shim YM; Kim J; Choi YS; Kim K; Shin S; Ahn Y; Kwon OJ; Kim H; Lee SJ; Chang WJ; Park K
J Thorac Oncol; 2013 Jul; 8(7):959-66. PubMed ID: 23722169
[TBL] [Abstract][Full Text] [Related]
7. Role of somatostatin analogue-based therapy in unresponsive malignant thymomas.
Palmieri G; Lastoria S; Montella L; Martignetti A; Lombardi G; Salvatore M; Bianco AR
Ann Med; 1999 Oct; 31 Suppl 2():80-5. PubMed ID: 10574161
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
[TBL] [Abstract][Full Text] [Related]
10. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
Conforti F; Zucali PA; Pala L; Catania C; Bagnardi V; Sala I; Della Vigna P; Perrino M; Zagami P; Corti C; Stucchi S; Barberis M; Guerini-Rocco E; Di Venosa B; De Vincenzo F; Cordua N; Santoro A; Giaccone G; De Pas TM
Lancet Oncol; 2022 Oct; 23(10):1287-1296. PubMed ID: 36096156
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
12. Multimodality treatments in locally advanced stage thymomas.
Hassan M; Seoud DE
Hematol Oncol Stem Cell Ther; 2009; 2(2):340-4. PubMed ID: 20118057
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
Pavel ME; Baudin E; Öberg KE; Hainsworth JD; Voi M; Rouyrre N; Peeters M; Gross DJ; Yao JC
Ann Oncol; 2017 Jul; 28(7):1569-1575. PubMed ID: 28444114
[TBL] [Abstract][Full Text] [Related]
14. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.
Loehrer PJ; Chen M; Kim K; Aisner SC; Einhorn LH; Livingston R; Johnson D
J Clin Oncol; 1997 Sep; 15(9):3093-9. PubMed ID: 9294472
[TBL] [Abstract][Full Text] [Related]
16. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
17. Thymoma. A retrospective study of 87 cases.
Park HS; Shin DM; Lee JS; Komaki R; Pollack A; Putnam JB; Cox JD; Hong WK
Cancer; 1994 May; 73(10):2491-8. PubMed ID: 8174044
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial.
Longo F; De Filippis L; Zivi A; Vitolo D; Del Signore E; Gori B; Diso D; Anile M; Venuta F; De Giacomo T; Coloni CF
Am J Clin Oncol; 2012 Apr; 35(2):105-9. PubMed ID: 21325939
[TBL] [Abstract][Full Text] [Related]
19. Thymoma and thymic carcinoma: therapeutic approaches.
Kurup A; Loehrer PJ
Clin Lung Cancer; 2004 Jul; 6(1):28-32. PubMed ID: 15310414
[TBL] [Abstract][Full Text] [Related]
20. Natural history and treatment of malignant thymoma.
Cowen D; Hannoun-Levi JM; Resbeut M; Alzieu C
Oncology (Williston Park); 1998 Jul; 12(7):1001-5; discussion 1006. PubMed ID: 9684271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
